This is the one as the saying goes that you have all been waiting for! Poractant entered the scene in Canada a few years ago with a lot of promise as a great alternative to the bovine source generally used here. The volume of administration was about half and as the use of MIST/LISA rose in popularity the option to use the lower volume was of interest to many. A study out of London Ontario demonstrated however that the bovine form could be used for LISA/MIST successfully and was written about in Less Invasive Surfactant Administration with High Volume Surfactant.
What about if we look at a real head to head comparison looking at meaningful outcomes like length duration of respiratory support? To do so would require a fairly large sample and would generally be difficult to accomplish but us Canadians opted for a study design to allow this to move forward with a sample size that for a neonatal study I think at least were admirable!
The Study
The study design here was a prospective comparative effectiveness cohort study of babies all born under 32 weeks at 13 NICUs across Canada. The study in question was entitled Poractant alfa versus bovine lipid extract surfactant: prospective comparative effectiveness study and is authored by many I consider colleagues and friends! To do this study each centre agreed to start off for 6 months with the bovine surfactant for any baby that had respiratory distress syndrome and in the opinion of the team needed surfactant. After that period each centre switched to poractant for an additional 6 months. This was a pragmatic trial designed to be less rigid with respect to criteria for intubation and allow for a “real world” determination of effect of using one surfactant vs another. While the study was not randomized the collection of outcome data relied on trained abstractors for the Canadian Neonatal Network in each centre. The authors determined that to see a difference in the primary outcome would require 484 patients per surfactant group. What they obtained in terms of recruitment is shown below.
The Results Please
I realize you have been waiting with excitement about what they could have found. Sadly they didn’t find too much!
There was no difference in length of ventilation or for that matter some important outcomes like number of doses of surfactant needed (if one group needed more might they be less effective), BPD, mortality and length of stay. The authors did note a difference in rates of MIST/LISA favouring the poractant group but when they controlled for that variable still found no difference in outcomes. Important to note that though since use of MIST/LISA may reduce the outcome of interest itself but alas no difference.
As with many studies people start digging and looking at secondary outcomes to see if there is anything of interest that pops up. It is worth noting here that whatever is found based on this study design would be an association so one must be careful not to jump to causation which may or may not be at play. For fun though let’s look at a couple of things that cropped up.
When you look at the subgroup of babies 28 +0 to 31+6 weeks an increased rate of pneumothorax creeps into the picture if you received poractant. On the other hand a reduction in days of non-invasive ventilation in favour of poractant comes into play for the same cohort. There of course is the possibility given these are secondary outcomes that these came about by chance. I did find it interesting about the pneumothorax issue though as early in the study when our centre was using poractant questions came up from our staff about a perceived increase in pneumothoraces with use of poractant. In other words the findings are in keeping with what our own units experience was so I can’t help but wonder if there is something there!
What the study does in my mind is demonstrate that if you wish to use either surfactant you may. I suppose then it comes down to comfort and in part whether you believe that use of a lower volume surfactant is better for administration with MIST/LISA. If that is the case then your choice would be poractant. If you don’t care however then it may come down to cost. There has been a difference in cost but I do wonder if the gap may close with demonstration of similar efficacy in this study. If people are indifferent to utility of the two then cost will certainly be a variable to consider!
At this point your head is likely spinning when it comes to managing the PDA. Should we treat it early, late or not at all? My last post was about benign neglect which may be well and good for the unit you work in but if you believe that these ducts can cause problems and want to treat them then you can choose from indomethacin, ibuprofen or paracetamol. Paracetamol (tylenol as you may know it better) is an old dog that has learned some new tricks. The former two drugs can be harder on the kidneys so with some recent data suggesting paracetamol may be equally effective to the other two, interest has grown. I had trouble at first understanding how this drug could help close a PDA since the other two I knew were effective through their anti-prostaglandin activity. It turns out that paracetamol is as well but just through a different mechanism. Paracetamol’s effect is likely through inhibition of the second active site on the prostaglandin H2 synthase, the peroxidase (POX) component.
Oral or IV
If you asked most people which route would be more effective the guess would be IV. Oral meds take time to be absorbed so wouldn’t you want a drug that goes straight to the target tissue as quickly as possible? The answer at least from what we learned with ibuprofen was no. There is in fact a cochrane review on the subject entitled Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. The conclusion favoured oral dosing and the reason for the greater benefit it turns out has to do with that slow absorption I talked about. While the IV dose will get the drug going where it needs to go faster and give you a quicker peak, the slow absorption of the drug gives you a longer time with a drug level above the blood level required to have the desired effect on ductal closure. In other words, slow and steady wins the race. It’s not surprising then that as knowledge and use of paracetamol spreads that similar questions would arise. This in fact led to a retrospective study looking at this exact question. Gover et al published Oral versus intravenous paracetamol for patent ductus arteriosus closure in preterm infants. which sought to examine the difference in the two routes of administration for 50 infants in their unit that received the drug for closure of a hemodynamically significant PDA. They excluded any infants who had received treatment for a PDA previously or paracetamol for pain relief so that they could really restrict the exposure to just closure of the PDA. They defined hemodynamically significant as a “moderate to large PDA, coupled with evidence of shunt burden, myocardial compromise, and continued need for significant respiratory support.” The drug was given from 3-7 days and was at the discretion of the Neonatologist. Longer courses were given for PDAs that were still open at 3 days and dosing was otherwise the same.
What Did They Find?
In terms of effectiveness the following figure maps out what happened with both oral and IV routes. For the whole 50 patients, 56% achieved closure after one course. Although the numbers are of course small, if you look at the oral group 15/19 or 79% had closure after one course vs 8/20 or 40% with IV alone. That’s quite a difference although again numbers are small here so we have to be careful about jumping to too big a conclusion (although it is in the direction we might have expected from the ibuprofen data). As this was not a randomized study it is difficult to know for certain that other factors were not at play here to explain the difference in closure rates but the authors did attempt to adjust for that and still found a benefit to oral administration.
Could this be explained by a difference in paracetamol levels in the blood? This is what I wondered about earlier in this post so maybe there is something to that? The authors looked at this as well by searching for a difference in trough levels prior to the 5th dose (no different). While it is tempting to write this off as a possibility then it is worth noting this is just one level in time. This was not a prospective, randomized study where serial levels could be taken to establish a pharmacokinetic patterns for the levels. While the one level is not different based on route I can’t help but wonder if these results are indeed real could the levels be above the minimum threshold for ductal closure longer.
An RCT will be needed to look at determining an answer here for sure but this is a great start no doubt. One thing that I can’t help but wonder about in this retrospective study is the “why” each Neonatologist chose oral vs IV. My guess is that in most cases the sicker the baby the more likely they were to receive IV. Babies who were quite sick on vasopressors or had demonstrated poor gut perfusion on ultrasound may have been more likely to get the IV form. These same patients are expected to have greater degrees of systemic inflammation and that is not good for ductal closure. Is the worse effect of IV therapy related to the drug itself or is it related to the overall state of the baby making closure less likely in the presence of inflammation?
I look forward to seeing a prospective study on this but maybe when possible for the time being it wouldn’t hurt when possible to give paracetamol orally? Interesting story that we will hear more about!
I don’t think you can be a Neonatal blogger without writing about the patent ductus arteriosus from time to time. It’s been a little while so when something floats past my desk that I find interesting I share it with you. When that article is Canadian and written by someone I collaborate with on the Canadian Pediatric Society Fetus and Newborn Committee I am even more apt to do so. In the last few years the idea of letting nature take its course with respect to the PDA has been growing. The evidence is lacking that treatment for most infants in the first two weeks of life makes a difference to important pulmonary outcomes ie. BPD. There is a growing movement asking whether treatment at all really makes a difference to these infants or whether we should just be managing the medical complications of increased pulmonary bloodflow with diastolic steal from the kidneys and intestine. The alternative of course is to treat these infants most commonly with NSAIDs and hope that side effects such as renal impairment and spontaneous intestinal perforation don’t happen. Full disclosure, I was raised to find the PDA and if hemodynamically significant treat it, so that has been my general approach. I am open to suggestion though so without further adieu let’s talk about a recent Quebec study on the topic.
University of McGill in Montreal
Anchored by Dr. Altit with the lead author being De Carvalho Nunes the experience at this hospital was recently published as Natural evolution of the patent ductus arteriosus in the extremely premature newborn and respiratory outcomes. The authors looked a specific population of infants born at <29 weeks gestational age (214 infants in total) and importantly had a reasonable number of small infants >26 weeks at birth (84) to see what happened to their PDAs in the long run. Many years ago the unit adopted a non-intervention policy with respect to treatment of PDAs and since 2015 were in a new hospital. This afforded them the opportunity to look retrospectively at a modern cohort of infants all cared for in the same environment from Feb 2015 – Sept 2019 and see what happened to respiratory morbidity over time. While this was retrospective and lacks a control group the concept here was that one could look at the rate of BPD over time and see if it was static, rising or falling and in turn you could also compare to the Canadian Neonatal Network (not done in this study) to see if your approach was leading to all sorts of morbidity.
What did they find?
The authors chose to standardize the definition of BPD:
Grade I (nasal flow cannula <1 L/min with FiO2 ≤ 70%; nasal cannula with flow of 1 to 3 L/min and FiO2 between 22 and 29%; CPAP, noninvasive positive pressure ventilation [NIPPV] or nasal cannula with flow >3 L/min with FiO2 of 21%),
Grade II (nasal flow cannula <1 L/min with FiO2 > 70%; nasal cannula with flow of 1 to 3 L/min and FiO2 ≥ 30%; CPAP, NIPPV or nasal cannula with flow >3 L/min with FiO2 between 22 and 29%; invasive mechanical ventilation [IMV] with FiO2 of 21%)
Grade III (NIMV, NIPPV or nasal cannula with flow >3 L/min with FiO2 ≥ 30%, IMV with FiO2 > 21%).
When looking at the total population including after discharge 91% of all babies greater than or equal to 26 weeks experienced ductal closure without intervention. Secondly, if you look under 26 weeks the results were hardly any different with 90% closing. Before discharge from the hospital 66% of the larger infants experienced closure prior to discharge and 76% of those under 26 weeks. Interesting finding that more infants under 26 weeks by percentage had closure.
Looking at the respiratory outcomes a total of 77% had BPD under 26 weeks of varying severity compared to 40% in the larger infants. Other morbidities were not different.
Interestingly the authors also noted a decline in Grade 2 BPD over the 5 year study.
Thoughts on the results
It’s important to look at the overall results from the Canadian Neonatal Network to see how this group compares to the rest of the country. What follows is not perfect but its a start for a discussion.
This includes all babies in the CNN under 1500g. If we use <1250g as a rough cutoff for under 29 weeks you can see that by weight the rate of chronic lung disease ranges from 30 – 100%. At 77% under 26 weeks which corresponds to babies around 750g or less (some are a little more) then the rate should be somewhere between 60 – 80% if you count babies 500 – 750g. I would say the rate of 77% overall is not bad in terms of comparison. Secondly if you look at the distribution of CLD for this group it was at their centre it was 47, 24 and 7% for Grade 1 – 3 respectively. This is particularly interesting as when you look at mild, moderate and severe in the bars above it would suggest their babies on average with a “benign neglect” approach are more mild. This approach is looking up!
One thing that I note though is that the rate of postnatal steroid use in this group was 75% under 26 weeks and 22% for those from 26-28 weeks. This represents a large increase over the mean in the CNN back in 2019 of 11.9% for postnatal steroid use. The babies under 26 weeks were also ventilated invasively for a median of 29 days. That seems a little long to me but there are no comparisons with the CNN to know for sure.
I can’t help but wonder if you are trading short term pain for long term gain. It’s hard to argue with the long term results in terms of a shift towards better rates of lower grade BPD. I do wonder though if the eventual closure of the PDA is being helped along with use of more postnatal dexamethasone. There is some data suggesting increased rates of closure with use of dexamethasone so maybe what is going on here is that rather than using NSAIDs there is a shift to long durations of ventilation and increased rates of dexamethasone use. Something for the authors to look at though.
With everything there are trade offs so maybe less NSAID use means longer ventilation and more postnatal steroids but in the end the pulmonary outcome is better? I see a prospective RCT coming to eventually settle this debate!
Jaundice has to be one of the most common issues facing newborns and their families. Whether in the NICU or on the post-partum floor all babies get jaundiced to a certain degree and some become so much so that they require treatment. Many centers the world over have developed home phototherapy programs to allow treatment to be done at home and they are known to be effective. In Sweden such programs exist and in theory sending infants home rather than keeping them in hospital could have positive effects for both the infant and parent dyad in terms of bonding. Keeping the infants in hospital and in particular over the last couple years when in many places of the world COVID protocols made visiting more difficult there is the real potential to disrupt bonding if a baby is otherwise ready for discharge. Researchers in Sweden with such programs in Uppsala recently decided to explore this question about bonding so here we go.
The Study
This was a multicentre study in Sweden by Pettersson M et al entitled Home phototherapy of term neonates improves parental bonding and stress: findings from a randomised controlled trial. The study intended to enroll 250 infant-parent pairs into an RCT comparing in-hospital phototherapy to home phototherapy and determine the status of bonding between child and parents at various time points. The inclusion criteria required infants to be >36 weeks at birth, have non-immune jaundice (DAT -ve) and have a bilirubin at inclusion from 300-400 micromol/L from 48 – 60 hours of age. Infants with asphyxia and weight loss >10% were excluded. Infants were also excluded if their parents did not speak Swedish or if the physician felt they would not be able handle home phototherapy.
In both environments treatment was provided with a biliblanket or overhead blue lights 25 cm from the skin which the infant would lay on or be placed under. These infants did not have severe bilirubin levels so it appears they had only standard phototherapy. This makes sense as babies with higher risk would not be suitable for consideration of home phototherapy.
Several validated tools were used to determine such things as bonding, risk of depression and stress. The primary outcome was based on use of the Postpartum Bonding Questionnaire (PBQ). Higher scores indicate worse bonding. The sample size was calculated on results from previous studies showing a mean (SD) of 10.7 (8.5) in 250 newborns with 90% power to detect a three-point difference in mean PBQ-sum for mothers at the 5% significance level, with a pre-planned interim analysis after 125 inclusions.
Enrollment was slow and after the preplanned analysis it was decided to stop the study recruitment and see where the results landed.
The Findings
Both groups of infants were treated for a total of about 4 days with testing for bilirubin levels and treatment with phototherapy (about 18 hours of total treatment both groups). The results of the PBQ found a statistical difference in measures of bonding favouring the home phototherapy group as found in the table below at both discharge and 4 months.
Interestingly when breaking down the results by mothers and fathers there was no impact on bonding for the fathers after this four day period of investigation and treatment at hospital vs in the home but at both time points it was the mother that drove the benefit seen. This likely speaks to differences in the way mothers and fathers experience bonding or perhaps how they process threats to it. No differences in stress could be found between the two groups but it is important to note that the small sample size and the fact that it was a secondary outcome make it difficult to say with certainty that there is no impact on stress.
Thoughts
You would be well within your rights to say “so what? It’s what we expected”. The difference seen in bonding while favouring the at home group has statistical significance but I am not sure to what degree this represents clinical significance. Can you truly perceive a difference in bonding based on a two point difference? Would that be meaningful functionally in the home in the way that parents relate to and respond to their infant? Not sure.
What I think we can say though is that the direction of the effect is certainly positive. We can also say from a systems standpoint that not only is phototherapy using a biliblanket safe and effective but it also moves care to the home and thereby creates room in the hospital for babies who truly need to be admitted.
Given the direction of the effect I think what the study does is provide one more argument aside from improving patient flow to aid in the establishment of home phototherapy programs. There are benefits not only to the family from an earlier discharge but also to some degree improvements in bonding certainly between mother and baby. This brief four day period has impacts that can last all the way out to four months. If you were looking for some evidence to support building such a program, maybe this will help!
Every parent the world over waits for that moment after birth when they first hear the cry of their child. The cry is a sign of health, of vigour and a relief that all should be ok. I had never questioned when the infant cry develops but one thing is for sure, it doesn’t matter whether you are born at 25 , 30 or 37 weeks, the babies all seem to make it after delivery. Much like suck, rooting and swallowing which we know begin in utero as we can see fetal swallowing movements the question is does cry begin in utero.
Evidence for an In-Utero Start
Before I get into the answer to this let me address the title question. A cry is produced as a baby exhales and moves air in a turbulent fashion across the vocal cords. Since a fetus is not breathing air it would seem impossible for a cry to be produced by a fetus. It doesn’t mean though that a fetus can’t try to at least practice and get ready for birth.
Back in 2005, a research team from New Zealand sought to answer this question in their paper Fetal homologue of infant crying. The authors described a case of a 33 week infant who was exposed to an artificial larynx generating a sound on the maternal abdomen while she was undergoing an ultrasound. The artificial larynx produced a vibroacoustic stimulation (VAS) after first keeping monitoring the fetus with ultrasound for a period of 20 minutes. The duration of the VAS was for 40 seconds and during this time the fetus was found to turn its head upon hearing the VAS and appeared to startle.
As per the authors the fetus underwent the following steps after the stimulation.
“There is a brief expiration that is followed by a deep inspiratory phase with a subsequent pronounced expiratory phase. This expiration is associated with jaw opening, taut tongue, and chest depression (fig 2). It is immediately followed by three augmented breaths with progressive increase in chest rise and head tilt (fig 3).”
At the end of this episode the chin was found to be quivering. This as I see it is the best and first description of fetal crying. While it doesn’t make a sound I believe at least that this is the beginning of an important step in development that will prepare the infant after birth to clear its lungs and inflate them with air.
The question now I ask is when does this develop? As I mentioned earlier the ability to cry is definitely present in preterm infants at pretty much any gestational age I have seen all the way down to 22 weeks. Much like other reflexes present at birth and the swallowing function mentioned earlier this must develop for a reason and I am hopeful that future work will uncover when this first appears and eventually add an explanation of what function this in-utero crying movements serve!
For commentary on this including a video of the first and second cry for this infant have a look at the full video below
